Comparative Pharmacology
Head-to-head clinical analysis: STATROL versus TRIACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STATROL versus TRIACORT.
STATROL vs TRIACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
10 mg orally once daily
10-20 mg orally once daily
None Documented
None Documented
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine.
Category C
Category C
Otic Antibiotic/Corticosteroid
Corticosteroid